The Case of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis
Year of publication: |
2005
|
---|---|
Authors: | Sorensen, Jan ; Andersen, Lis S. |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 23.2005, 3, p. 289-298
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Cost-analysis | Disease-modifying-antirheumatics | Etanercept | Infliximab | Rheumatoid-arthritis | Tumour-necrosis-factor-antagonists |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK
Barbieri, Marco, (2005)
-
Nguyen, Christine M., (2012)
-
Quality of Life in Patients with Rheumatoid Arthritis: Which Drugs Might Make a Difference?
Blumenauer, Barbara, (2003)
- More ...
-
Analytical methods to assess the impacts of activity-based funding (ABF): A scoping review
Valentelyte, Gintare, (2021)
-
Assessing direct healthcare costs when restricted to self-reported data: A scoping review
Jabakhanji, Samira B., (2021)
-
Analytical methods to assess the impacts of activity-based funding (ABF) : a scoping review
Valentelyte, Gintare, (2021)
- More ...